Alterity Therapeutics Limited - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ATHE Nasdaq 2836 alteritytherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alterity Therapeutics Limited

Ather Energy (NSEI:ATHERENERG) Stock Sees Modest Fair Value Lift On Stronger Growth Assumptions - Oct 9th, 2026 11:19 am
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference - Oct 9th, 2026 5:05 am
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders - Oct 5th, 2026 5:05 am
Alterity Therapeutics CEO speaks with Proactive at the ASX SMIDcaps Conference - Sep 23rd, 2026 3:07 am
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 - Sep 3rd, 2026 5:05 am
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434 - Aug 12th, 2026 5:05 am
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference - Aug 6th, 2026 5:25 am
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update - Jul 30th, 2026 5:25 am
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026 - Jul 21st, 2026 5:25 am
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy - Jul 7th, 2026 5:05 am
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy - Jun 9th, 2026 5:05 am
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy - May 19th, 2026 5:25 am
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy - May 11th, 2026 5:25 am
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 - May 7th, 2026 5:25 am
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update - Apr 30th, 2026 5:25 am
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy - Apr 27th, 2026 5:25 am
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors - Apr 17th, 2026 5:25 am
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting - Apr 16th, 2026 5:25 am